Savara (NASDAQ:SVRA) Stock Picked Up by Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. started coverage on shares of Savara (NASDAQ:SVRA – Get Free Report) in a note issued to investors on Wednesday, Benzinga reports. The firm set an “overweight” rating and a $12.00 price target on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 158.06% from the stock’s current price.

SVRA has been the subject of a number of other reports. Royal Bank Of Canada set a $10.00 price objective on Savara in a research note on Wednesday. Citigroup restated a “market outperform” rating on shares of Savara in a report on Wednesday. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.25.

Get Savara alerts:

Check Out Our Latest Stock Analysis on SVRA

Savara Stock Down 2.7%

Shares of Savara stock opened at $4.65 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The stock has a market cap of $955.39 million, a price-to-earnings ratio of -8.02 and a beta of 0.20. The firm’s 50-day moving average is $5.35 and its two-hundred day moving average is $5.42. Savara has a 1 year low of $3.34 and a 1 year high of $7.01.

Savara (NASDAQ:SVRA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). As a group, research analysts expect that Savara will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in shares of Savara by 96.5% in the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock valued at $3,564,000 after acquiring an additional 320,572 shares during the period. Walleye Capital LLC purchased a new stake in Savara during the 2nd quarter valued at about $1,532,000. BlackRock Inc. acquired a new position in shares of Savara in the second quarter valued at about $76,966,000. Deutsche Bank AG acquired a new position in shares of Savara in the second quarter valued at about $5,328,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of Savara in the second quarter worth about $42,977,150. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

(Get Free Report)

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.

Featured Articles

• Five stocks we like better than Savara
• Rivian Escapes the EV Graveyard—But Can It Stay Alive?
• Allient’s Data Center and Defense Momentum Is Raising the Stakes
• Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
• Lamb Weston’s Turnaround Is Starting to Look Real

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.